You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Clinical Advances in

Treatment of Moderate to Severe Asthma

The treatment landscape for asthma continues to evolve, with recent advances in therapies and inhaler technology. Triple fixed-dose ICS/LABA/LAMA therapy has demonstrated improved asthma outcomes vs dual therapy. Biologics have shown clinical benefits in severe asthma and a common comorbidity, CRSwNP. The COVID-19 pandemic poses an additional challenge. Clinicians need guidance in optimizing therapy based on disease characteristics, comorbidities, and patient preferences, so they can effectively control asthma by implementing the latest clinical evidence into their treatment decision making process.

Supported by independent funding from


CME Activities

Related Resources

Downloadable Slide Kit

Treating Moderate to Severe Asthma

Downloadable slides on moderate to severe asthma, dual bronchodilation therapy, CRSwNP and COVID-19


Clinical Articles

Omalizumab efficacy and safety in nasal polyposis: results from two parallel, double-blind placebo-controlled trials.  

Indacaterol/glycopyrronium/mometasone furoate improves lung function and reduces exacerbations versus long-acting β2-agonist/inhaled corticosteroid standard-of-care in patients with uncontrolled asthma: the phase III IRIDIUM study.  

Non-inferior improvement in asthma quality of life and favourable benefit in terms of lung function and asthma control with inhaled combination of indacaterol/glycopyrronium/mometasone furoate once daily compared with the "loose" combination of salmeterol/fluticasone twice daily plus tiotropium in patients with uncontrolled asthma: results of the phase III ARGON study.  

Nonatopic severe asthma might still be atopic: sensitization towards Staphylococcus aureus enterotoxins  

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19  

Do Chronic Respiratory Diseases or Their Treatment Affect the Risk of SARS-CoV-2 Infection?  

Related Links

See All

Steering Committee

Claus Bachert, MD, PhD

Upper Airways Research Laboratory
Clinics ENT-Department
University Hospital Ghent
Ghent, Belgium

Enrico Heffler, MD, PhD

Associate Professor of Internal Medicine
Department of Biomedical Science
Humanitas University
Pieve Emanuele, Milan, Italy

Marc Humbert, MD, PhD

Marc Humbert, MD, PhD

Professor of Respiratory Medicine
Université Paris-Saclay
Department of Respiratory and Intensive Care Medicine
Hôpital Bicêtre
Le Kremlin-Bicêtre, France

Valerie J. Lund, MB, BS, FRCS, FRCSEd

Professor Emeritus of Rhinology
University College London
London, United Kingdom

Jadwiga A. Wedzicha, MD

Professor of Respiratory Medicine
Respiratory Division
National Heart and Lung Institute
Imperial College London
London, United Kingdom

Mina Gaga, MD, PhD

President, Central Health Council
Director, 7th Respiratory Medicine
Department and Asthma Center,